Luxiq is a drug owned by Norvium Bioscience Llc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 24, 2017. Details of Luxiq's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7078058 | Corticosteroid-containing pharmaceutical composition |
May, 2017
(7 years ago) |
Expired
|
| US6126920 | Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition |
Mar, 2016
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Luxiq's patents.
Latest Legal Activities on Luxiq's Patents
Given below is the list of recent legal activities going on the following patents of Luxiq.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 13 Aug, 2018 | US7078058 |
| Maintenance Fee Reminder Mailed Critical | 26 Feb, 2018 | US7078058 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 13 Apr, 2010 | US7078058 |
| Correspondence Address Change Critical | 11 Sep, 2009 | US7078058 |
| Correspondence Address Change Critical | 02 Jul, 2007 | US7078058 |
| Change in Power of Attorney (May Include Associate POA) Critical | 14 Mar, 2007 | US7078058 |
| Correspondence Address Change Critical | 14 Mar, 2007 | US7078058 |
| Recordation of Patent Grant Mailed Critical | 18 Jul, 2006 | US7078058 |
| Patent Issue Date Used in PTA Calculation Critical | 18 Jul, 2006 | US7078058 |
| Issue Notification Mailed Critical | 28 Jun, 2006 | US7078058 |
US patents provide insights into the exclusivity only within the United States, but Luxiq is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Luxiq's family patents as well as insights into ongoing legal events on those patents.
Luxiq's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Luxiq's generic launch date based on the expiry of its last outstanding patent is estimated to be May 24, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Luxiq Generic API suppliers:
Betamethasone Valerate is the generic name for the brand Luxiq. 11 different companies have already filed for the generic of Luxiq, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Luxiq's generic
How can I launch a generic of Luxiq before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Luxiq's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Luxiq's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Luxiq -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.0012 | 10 Aug, 2007 | 1 | 26 Nov, 2012 | 24 May, 2017 | Deferred |
Alternative Brands for Luxiq
Luxiq which is used for treating skin diseases with corticosteroid-containing pharmaceutical compositions., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Norvium Bioscience |
| |||
About Luxiq
Luxiq is a drug owned by Norvium Bioscience Llc. It is used for treating skin diseases with corticosteroid-containing pharmaceutical compositions. Luxiq uses Betamethasone Valerate as an active ingredient. Luxiq was launched by Norvium Bioscience in 1999.
Approval Date:
Luxiq was approved by FDA for market use on 28 February, 1999.
Active Ingredient:
Luxiq uses Betamethasone Valerate as the active ingredient. Check out other Drugs and Companies using Betamethasone Valerate ingredient
Treatment:
Luxiq is used for treating skin diseases with corticosteroid-containing pharmaceutical compositions.
Dosage:
Luxiq is available in aerosol, foam form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.12% | AEROSOL, FOAM | Discontinued | TOPICAL |